SCHEMBL3707388

SCHEMBL3707388

Cc1ccc(C2CNCc3ccc(Cl)nc3O2)nc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3700062 0.82 CCR1 (0.30)
SCHEMBL3741207 0.81 LDHA (0.34)
SCHEMBL3745574 0.80 HTR2A (0.31)
SCHEMBL5580038 0.79 NISCH (0.32)
SCHEMBL3703919 0.78 SLC6A2 (0.32)
SCHEMBL3706863 0.75 MEN1 (0.38)
SCHEMBL3706859 0.75 MEN1 (0.38)
SCHEMBL3709410 0.74 HTR2A (0.30)
SCHEMBL10200444 0.74 HTR2A (0.40)
Hydrochloric Acid SCHEMBL2106541 0.72 HTR2A (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012064269-A1 COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES ASTRAZENECA AB (SE) 2012-05-18 WO disclosed
WO-2012064269-A1 COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES ASTRAZENECA AB (SE) 2012-05-18 WO disclosed
US-20120122843-A1 Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases ASTRAZENECA AB (SE) 2012-05-17 US disclosed